NASDAQ:MBRX

Moleculin Biotech Stock News

Healthcare > Biotechnology

Buy MBRX

*Your capital is at risk

$2.46

+0 (+0%)

At Close: Jun 03, 2026

Moleculin Biotech, Inc. (MBRX) Q1 2024 Earnings Call Transcript

11:44am, Monday, 13'th May 2024

Moleculin Biotech, Inc. [MBRX] Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO Jonathan Foster - EVP and CFO Paul Waymack - Senior CMO Jen

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

07:30am, Monday, 13'th May 2024

– Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subject

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

08:30am, Thursday, 09'th May 2024

Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an acc

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

08:45am, Wednesday, 08'th May 2024

HOUSTON , May 8, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

08:55am, Tuesday, 07'th May 2024

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st – 7th line,

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

09:00am, Thursday, 02'nd May 2024

Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Com

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

08:50am, Wednesday, 01'st May 2024

– Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Mole

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

09:45am, Thursday, 25'th Apr 2024

Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a ful

PRISM MarketView – Biotech Breakfast

07:00am, Monday, 22'nd Apr 2024

Roche's Alecensa Gets FDA Green Light; ImmunityBio Gains as PDUFA Date Approaches for Bladder Cancer Drug; Key Drug Trial Failures in 2024 New York, N.Y., April 22, 2024 – PRISM MarketView – Heal

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

08:30am, Thursday, 18'th Apr 2024

– Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

08:30am, Wednesday, 10'th Apr 2024

Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte cultures Results clearly aligned with lack of drug

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by